VIENNA–(BUSINESS WIRE)–AOP Health announced results of ropeginterferon alfa-2b (BESRMi®) from its CONTINUATION-PV clinical study in patients with polycythemia vera (PV), a rare form of blood cell cancer. Professor Heinz Gisslinger of the Medical University of Vienna, Austria1 announced the findings in an abstract accepted for presentation at the prestigious European Hematology Association (EHA) Annual Congress 2023.
Link all’abstract di CONTINUATION-PV.
Reducing the risk of thrombotic events is an important goal in the treatment of PV
The abstract accepted for presentation at the EHA 2023 Annual Meeting focuses on the proportion of time individual patients spent with peripheral blood cell counts that meet recommended targets to minimize thrombotic complications.
The original text of this announcement, written in the source language, is the official version which is authentic. Translations are offered solely for the convenience of the reader and must refer to the text in the original language, which is the only legally valid one.
Contacts
More information
BY Isolde Fally
AOP Orphan Pharmaceuticals GmbHMembro dell’AOP Health Group
Isolde.Fally@aop-health.com+43-676-500 4048